Brighten breaks down how perimenopause and menopause shift insulin sensitivity, fat distribution, appetite, and recovery and where glucagon-like peptide-1 (GLP-1) receptor agonists (think semaglutide/Ozempic, Wegovy, liraglutide, tirzepatide as a related incretin therapy) can fit safely alongside hormone therapy, lifting, protein, and smart lab work
The phosphorylation of BCKD inhibits the enzyme, whereas, dephosphorylation activates it
Nitric oxide synthase activity in major depressive episodes before and after antidepressant treatment: Results of a large casecontrol treatment study
Just having experts, our own physicians are board certified in obesity medicine
Repetitive reports (if more than one version of the same study was retrieved, only the most recent one was used
Gallbladder risk is a known tradeoff of GLP-1 therapy, and managing it well means working with a provider before and during treatment, not waiting until symptoms escalate